Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY News - neurodegeneration

MedXY AI/MedXY News/Tag: neurodegeneration

MedXY News

EnglishTag

neurodegeneration

27 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

Serum Ferritin and Inflammation in Isolated REM Sleep Behavior Disorder: Insights from Longitudinal Cohort Studies

Clinical Updatesneurodegenerationinflammation

Serum Ferritin and Inflammation in Isolated REM Sleep Behavior Disorder: Insights from Longitudinal Cohort Studies

By MedXY|Aug 6, 2026

This review explores the role of dysregulated iron metabolism and inflammation, particularly elevated serum ferritin, in isolated REM sleep behavior disorder (iRBD) as a prodromal stage of neurodegeneration, synthesizing recent longitudinal

Automated Speech Analysis in Primary Progressive Aphasia: Diagnostic, Anatomical, and Pathological Insights

Clinical Updatesneurodegeneration

primary progressive aphasia

Automated Speech Analysis in Primary Progressive Aphasia: Diagnostic, Anatomical, and Pathological Insights

By MedXY|Aug 6, 2026

Automated speech analysis of brief connected speech accurately identifies clinical, anatomical, and neuropathological variants of primary progressive aphasia, facilitating scalable diagnosis and monitoring.

Survival Estimates and Predictors in Genetic Frontotemporal Dementia: Insights from an International Retrospective Cohort Study

Clinical UpdatesneurodegenerationC9orf72

Survival Estimates and Predictors in Genetic Frontotemporal Dementia: Insights from an International Retrospective Cohort Study

By MedXY|Aug 5, 2026

This review synthesizes international evidence on survival in genetic frontotemporal dementia (FTD), highlighting key predictors such as age at onset, clinical phenotype, and motor symptoms, and discusses implications for patient care and t

Decoding Tofersen’s CNS Penetrance and Efficacy in SOD1-ALS Through Autopsy Tissue Analysis

NeurologyAntisense oligonucleotideCentral Nervous System

Decoding Tofersen’s CNS Penetrance and Efficacy in SOD1-ALS Through Autopsy Tissue Analysis

By MedXY|Jul 8, 2026

This study unveils tofersen’s distribution and potent SOD1 reduction within the CNS of SOD1-ALS patients, utilizing autopsy tissues from clinical trial participants, confirming anticipated pharmacokinetic and pharmacodynamic effects.

Levacetylleucine Shows Promising Safety and Efficacy in Treating Ataxia-Telangiectasia: Phase 3 Trial Findings

Neurologyataxia-telangiectasiaclinical trial

Levacetylleucine Shows Promising Safety and Efficacy in Treating Ataxia-Telangiectasia: Phase 3 Trial Findings

By MedXY|Jul 8, 2026

A phase 3 randomized, placebo-controlled crossover trial demonstrates that levacetylleucine significantly improves neurological function in ataxia-telangiectasia patients with a favorable safety profile.

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia: An Integrative Review

Clinical Updatesfrontotemporal dementianeurodegeneration

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia: An Integrative Review

By MedXY|Jun 27, 2026

This review synthesizes current evidence on CSF TMEM106B levels in FTLD, highlighting their associations with disease severity, genetic variants, brain atrophy, and clinical progression, emphasizing TMEM106B’s potential as a biomarker

Protein Misfolding in the Gut: A Window into Future Neurodegeneration

Gastroenterologybiomarkergastrointestinal biopsy

Protein Misfolding in the Gut: A Window into Future Neurodegeneration

By MedXY|Apr 23, 2026

GI biopsies reveal misfolded proteins years before neurological symptoms appear, offering a new biomarker for early neurodegenerative disease prediction and intervention.

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

NeurologyALSclinical trial

PrimeC Combination Therapy Shows Potential to Slow Functional Decline in Amyotrophic Lateral Sclerosis: Insights from the PARADIGM Trial

By MedXY|Mar 30, 2026

The Phase 2b PARADIGM trial demonstrates that PrimeC—a novel combination of celecoxib and ciprofloxacin—is safe and significantly slows functional decline in ALS patients over 18 months, offering new hope for multi-target neuroprotective st

Impact of Long-Term Ambient Air Pollution on the Pathogenesis and Clinical Progression of Motor Neuron Disease

Cardiologyair pollutionenvironmental health

Impact of Long-Term Ambient Air Pollution on the Pathogenesis and Clinical Progression of Motor Neuron Disease

By MedXY|Mar 20, 2026

Recent evidence from a large-scale Swedish study reveals that long-term exposure to fine and coarse particulate matter and nitrogen dioxide significantly increases the risk of Motor Neuron Disease and accelerates functional decline and mort

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

NeurologyALSclinical trials

PrimeC Shows Significant Long-term Functional Benefit and Reduced Mortality in ALS: Insights from the PARADIGM Trial

By MedXY|Mar 18, 2026

The Phase 2b PARADIGM trial reveals that PrimeC, a novel oral combination therapy, is safe and significantly slows functional decline and reduces the risk of death or hospitalization in ALS patients over 18 months.

Somatic Mosaicism in the Motor Cortex: A New Frontier in Understanding Sporadic ALS Pathogenesis

NeurologyALSFUS Protein

Somatic Mosaicism in the Motor Cortex: A New Frontier in Understanding Sporadic ALS Pathogenesis

By MedXY|Mar 12, 2026

This study identifies somatic gene mutations in excitatory neurons of the motor cortex as a potential driver of sporadic ALS, challenging the traditional view of the disease’s genetic origins.

Spinal Cord Tau and Protein Copathologies Associated With Chronic Traumatic Encephalopathy: A Detailed Clinical-Pathological Analysis

NeurologyCTEneurodegeneration

Spinal Cord Tau and Protein Copathologies Associated With Chronic Traumatic Encephalopathy: A Detailed Clinical-Pathological Analysis

By MedXY|Mar 11, 2026

This retrospective study identifies a high prevalence of spinal cord p-tau and protein copathologies in patients with Chronic Traumatic Encephalopathy (CTE), suggesting the existence of a ‘trauma-related encephalomyelopathy’ lin

Redefining CTE: New Autopsy Evidence Links Repetitive Head Impact to Extensive Spinal Cord Pathology

NeurologyCTEneurodegeneration

Redefining CTE: New Autopsy Evidence Links Repetitive Head Impact to Extensive Spinal Cord Pathology

By MedXY|Feb 10, 2026

A landmark autopsy study reveals that Chronic Traumatic Encephalopathy (CTE) involves extensive spinal cord pathology, including tau, TDP-43, and amyloid-β deposits. These findings suggest that repetitive head impacts trigger a widespread e

Higher Serum Klotho Levels May Protect Cognitive Function Against Age-Related Brain Atrophy

NeurologyAlzheimer diseaseneurodegeneration

Higher Serum Klotho Levels May Protect Cognitive Function Against Age-Related Brain Atrophy

By MedXY|Feb 6, 2026

Research indicates that circulating levels of the longevity protein klotho can moderate the relationship between cerebral atrophy and cognitive performance in older adults, suggesting a biological mechanism for cognitive resilience even in

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency

NeurologyAlzheimer's diseasebiomarkers

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency

By MedXY|Jan 7, 2026

A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and

Early CPAP Intervention May Mitigate Parkinson Disease Risk in Patients with Obstructive Sleep Apnea

NeurologyCPAP Therapyneurodegeneration

Early CPAP Intervention May Mitigate Parkinson Disease Risk in Patients with Obstructive Sleep Apnea

By MedXY|Jan 2, 2026

A massive cohort study of 11.3 million US veterans reveals that obstructive sleep apnea is an independent risk factor for Parkinson disease, but early treatment with CPAP significantly reduces this risk, particularly in women.

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

Cardiologycognitive impairmentDấu Hiệu Sinh Học Tim

Elevated Cardiac Biomarkers Serve as Early Indicators of Structural Brain Damage and Cognitive Decline: Insights from the Hamburg City Health Study

By MedXY|Dec 25, 2025

The Hamburg City Health Study reveals that elevated NT-proBNP and hs-cTnI are significantly linked to neurodegeneration and vascular brain injury. These cardiac biomarkers offer a non-invasive pathway for identifying patients at high risk f

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

Diabetes & Endocrinologydiabetesneurodegeneration

Diabetes and Dementia Biomarkers: Less Alzheimer’s Pathology but More Non‑AD Neurodegeneration in Cognitively Normal Adults

By MedXY|Nov 4, 2025

A pan‑European analysis (n=5,550) found diabetes was associated with lower odds of amyloid and p‑tau pathology in cognitively impaired patients, but with markers of neurodegeneration (total tau, medial temporal atrophy) in cognitively norma

Advances in Alzheimer’s Diagnosis: A Comprehensive Review of CSF and Blood Biomarkers

NeurologyAlzheimer's diseaseblood-based biomarkers

Advances in Alzheimer’s Diagnosis: A Comprehensive Review of CSF and Blood Biomarkers

By MedXY|Oct 20, 2025

This article reviews a systematic meta-analysis of 15 cerebrospinal fluid and blood biomarkers for Alzheimer’s disease, highlighting robust diagnostic performance of core markers T-tau, P-tau, and Aβ42 in clinical practice and researc

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

Neurologyclinical trialmultiple sclerosis

Simvastatin Fails to Slow Disability Progression in Secondary Progressive Multiple Sclerosis: Insights from the Phase 3 MS-STAT2 Trial

By MedXY|Jan 15, 2026

In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities